RIGL – Rigel Pharmaceuticals Inc.
RIGL — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
17.67
Margin Of Safety %
5
Put/Call OI Ratio
0.47
EPS Next Q Diff
0.35
EPS Last/This Y
-17.51
EPS This/Next Y
1.94
Price
40.12
Target Price
55.6
Analyst Recom
1.8
Performance Q
53.09
Upside
1,322.0%
Beta
1.17
Ticker: RIGL
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | RIGL | 41.31 | 0.56 | 0.21 | 3595 |
| 2026-07-14 | RIGL | 41.2 | 0.56 | 0.44 | 3605 |
| 2026-07-15 | RIGL | 41.17 | 0.56 | 0.24 | 3622 |
| 2026-07-16 | RIGL | 41.7 | 0.56 | 0.05 | 3643 |
| 2026-07-17 | RIGL | 40.49 | 0.55 | 0.47 | 3727 |
| 2026-07-20 | RIGL | 39.62 | 0.34 | 8.23 | 2858 |
| 2026-07-21 | RIGL | 39.29 | 0.38 | 0.17 | 2981 |
| 2026-07-22 | RIGL | 37.83 | 0.39 | 1.43 | 2979 |
| 2026-07-23 | RIGL | 36.79 | 0.39 | 2.32 | 2990 |
| 2026-07-24 | RIGL | 36.72 | 0.40 | 0.09 | 3028 |
| 2026-07-27 | RIGL | 37.34 | 0.44 | 0.11 | 2917 |
| 2026-07-28 | RIGL | 38.52 | 0.44 | 0.58 | 2918 |
| 2026-07-29 | RIGL | 39.03 | 0.44 | 0.10 | 2913 |
| 2026-07-30 | RIGL | 38.01 | 0.44 | 0.24 | 2920 |
| 2026-07-31 | RIGL | 36.82 | 0.44 | 0.73 | 2944 |
| 2026-08-03 | RIGL | 37.32 | 0.45 | 0.39 | 2965 |
| 2026-08-04 | RIGL | 38.71 | 0.45 | 0.13 | 2979 |
| 2026-08-05 | RIGL | 40.55 | 0.44 | 0.93 | 3022 |
| 2026-08-06 | RIGL | 39.22 | 0.48 | 0.07 | 3099 |
| 2026-08-07 | RIGL | 40.15 | 0.47 | 0.21 | 3142 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | RIGL | 41.35 | -100.0 | -45.5 | 2.92 |
| 2026-07-14 | RIGL | 41.28 | -100.0 | -42.7 | 2.92 |
| 2026-07-15 | RIGL | 41.26 | -100.0 | -42.5 | 2.92 |
| 2026-07-16 | RIGL | 41.69 | -100.0 | -41.5 | 2.92 |
| 2026-07-17 | RIGL | 40.56 | -100.0 | -45.3 | 2.92 |
| 2026-07-20 | RIGL | 39.61 | -100.0 | -44.9 | 2.92 |
| 2026-07-21 | RIGL | 39.30 | -100.0 | -43.5 | 2.92 |
| 2026-07-22 | RIGL | 37.85 | -100.0 | -46.5 | 2.92 |
| 2026-07-23 | RIGL | 36.76 | -100.0 | -45.5 | 2.92 |
| 2026-07-24 | RIGL | 36.73 | -100.0 | -42.8 | 2.92 |
| 2026-07-27 | RIGL | 37.36 | -100.0 | -40.8 | 2.92 |
| 2026-07-28 | RIGL | 38.54 | -100.0 | -39.9 | 2.92 |
| 2026-07-29 | RIGL | 39.08 | -100.0 | -41.2 | 2.92 |
| 2026-07-30 | RIGL | 38.06 | -100.0 | -45.2 | 2.92 |
| 2026-07-31 | RIGL | 36.74 | -100.0 | -46.1 | 2.89 |
| 2026-08-03 | RIGL | 37.35 | -100.0 | -41.2 | 2.89 |
| 2026-08-04 | RIGL | 37.35 | -100.0 | -41.2 | 2.89 |
| 2026-08-05 | RIGL | 40.52 | -100.0 | -38.3 | 2.89 |
| 2026-08-06 | RIGL | 39.15 | -100.0 | -46.2 | 2.89 |
| 2026-08-07 | RIGL | 40.12 | -16.7 | -12.9 | 2.89 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | RIGL | -1.44 | -1.54 | 18.18 |
| 2026-07-14 | RIGL | -1.44 | -1.54 | 18.18 |
| 2026-07-15 | RIGL | -1.44 | -1.54 | 18.18 |
| 2026-07-16 | RIGL | -1.44 | -1.54 | 18.18 |
| 2026-07-17 | RIGL | -1.44 | -1.54 | 18.18 |
| 2026-07-20 | RIGL | -1.44 | -3.24 | 18.20 |
| 2026-07-21 | RIGL | -1.40 | -3.24 | 18.20 |
| 2026-07-22 | RIGL | -1.40 | -3.24 | 18.20 |
| 2026-07-23 | RIGL | -1.40 | -3.24 | 18.20 |
| 2026-07-24 | RIGL | -1.40 | -3.24 | 18.20 |
| 2026-07-27 | RIGL | -1.40 | -3.10 | 17.67 |
| 2026-07-28 | RIGL | -1.40 | -3.10 | 17.67 |
| 2026-07-29 | RIGL | -1.40 | -3.10 | 17.67 |
| 2026-07-30 | RIGL | -1.40 | -3.10 | 17.67 |
| 2026-07-31 | RIGL | -1.40 | -3.10 | 17.67 |
| 2026-08-03 | RIGL | -1.40 | -2.95 | 17.67 |
| 2026-08-04 | RIGL | -1.40 | -2.95 | 17.67 |
| 2026-08-05 | RIGL | -1.40 | -2.95 | 17.67 |
| 2026-08-06 | RIGL | -1.40 | -2.95 | 17.67 |
| 2026-08-07 | RIGL | -1.39 | -2.95 | 17.67 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.88
Avg. EPS Est. Current Quarter
1.22
Avg. EPS Est. Next Quarter
1.23
Insider Transactions
-1.39
Institutional Transactions
-2.95
Beta
1.17
Average Sales Estimate Current Quarter
80
Average Sales Estimate Next Quarter
91
Fair Value
41.95
Quality Score
100
Growth Score
54
Sentiment Score
50
Actual DrawDown %
23.2
Max Drawdown 5-Year %
-83.8
Target Price
55.6
P/E
2.46
Forward P/E
9.62
PEG
P/S
2.71
P/B
1.76
P/Free Cash Flow
9.45
EPS
16.32
Average EPS Est. Cur. Y
2.89
EPS Next Y. (Est.)
4.83
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
116.3
Relative Volume
0.81
Return on Equity vs Sector %
48.3
Return on Equity vs Industry %
64.4
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.02
EBIT Estimation
-12.9
◆
RIGL
Healthcare
$40.17
Swing / Pullback
Buy the dip on strong trends
WATCH
RSI
57.2
Range 1M
59.2%
Sup Dist
5.3%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-82.7%
EPS NY
24%
52W%
56.3%
Long-Term Value
Quality companies, undervalued
WATCH
🟢 BUY
+169.4% upside
Upside
+169.4%
Quality
100
MoS
5%
RIGL — P/E HistoricalBiotechnology
Rigel Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 172
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
RIGL
Latest News
—
Caricamento notizie per RIGL…
stock quote shares RIGL – Rigel Pharmaceuticals Inc. Stock Price stock today
news today RIGL – Rigel Pharmaceuticals Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RIGL – Rigel Pharmaceuticals Inc. yahoo finance google finance
stock history RIGL – Rigel Pharmaceuticals Inc. invest stock market
stock prices RIGL premarket after hours
ticker RIGL fair value insiders trading